Loading data for ATRC — first visit, this takes a few seconds.

Preisalarm

AtriCure Inc. (ATRC)

NasdaqGM: ATRC · Echtzeitkurs · USD

45.76

+0.99 (2.21%)

Zum Schluss: Aug 18, 2026, 8:00 PM

2.21% (1D)

Keine Daten verfügbar

Geld	n/a
Marktkapitalisierung	2.33 Mrd
Umsatz (TTM)	569.62 Mio
Nettogewinn (TTM)	10.55 Mio
Beta	1.23
EPS (ttm)	0.21
KGV (TTM)	217.9
Forward-KGV	105.98
KBV (TTM)	4.51
KUV (TTM)	4.09
Earnings Date	May 5, 2026

Brief	n/a
Volumen	866,606
Ø Vol. (20D)	910,843
Eröffnung	45.23
Vortagesschluss	44.77
Tagesspanne	44.40 - 46.34
52-Wk Range	25.36 - 46.34
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über ATRC

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a ...

[Mehr lesen]

Branche Medical Instruments & Supplies

Sektor Healthcare

IPO Datum Aug 5, 2005

Mitarbeiter 1,350

Börse NasdaqGM

Tickersymbol ATRC

Website https://www.atricure.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von AtriCure 534.53 Mio, ein Anstieg von 14.88% im Vergleich zum Vorjahr (465.31 Mio). Der Gewinn lag bei -11.45 Mio, ein Rückgang von -74.39 %.

Finanzberichte

Gewinnüberraschung

AtriCure hat die Quartalszahlen am Jul 23, 2026 veröffentlicht:

Umsatz von $153.6 Mio verfehlt die Erwartungen um $0, mit 12.83% Wachstum im Jahresvergleich.

EPS von 0.18 übertrifft die Erwartungen um 0.16, mit 228.57% Wachstum im Jahresvergleich.

Nächste Ergebnisveröffentlichung

AtriCure Inc. wird voraussichtlich die Quartalszahlen veröffentlichen am May 5, 2026, nach Börsenschluss.
Analysten erwarten einen Umsatz von ... Upgrade

Nachrichten

vor 1 Woche · MarketBeat

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

AtriCure (NASDAQ:ATRC) said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoptio...

vor 1 Woche · Motley Fool

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

The sale came at $38.42 per share, slightly below the day's market close, as AtriCure maintains its $2.0 billion market cap in the medical device sector.

vor 1 Woche · Motley Fool

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Prange's open-market disposition reduced her direct holdings by 14%, though she retains over 22,800 shares in the $2.0 billion medical device company.

vor 2 Wochen · Simply Wall St.

Project Horizon and Outlook Upgrade Might Change The Case For Investing In Inspire Medical Systems (INSP)

Inspire Medical Systems recently appointed AtriCure CEO Michael H. Carrel to its Board and committees, while long-serving director Casey M. Tansey plans to retire, as the company reported quarterly re...

vor 2 Wochen · Zacks

Are Options Traders Betting on a Big Move in AtriCure Stock?

Investors need to pay close attention to ATRC stock based on the movements in the options market lately.

Seite 1 von 2

AtriCure Inc. (ATRC)